ViroPharma Provides Update On Upcoming FDA Advisory Committee Meeting To Discuss Bioequivalence Of Locally Acting Gastrointestinal Drugs

 09.07.2008 06:13   medicalnewstoday.com

ViroPharma Incorporated (Nasdaq: VPHM) has been informed by U.S. Food and Drug Administration (FDA) that the July 23, 2008 meeting of its Advisory Committee for Pharmaceutical Science and Clinical Pharmacology is not intended to discuss specifically ViroPharma's Vancocin(R) (vancomycin hydrochloride capsules) or any other drug products.

World Gastroenterology